ClinConnect ClinConnect Logo
Search / Trial NCT06086561

Longitudinal Measurements of Flow in Cerebrospinal Fluid Shunts With a Wireless Thermal Anisotropy Measurement Device

Launched by RHAEOS, INC. · Oct 10, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new device designed to measure the flow of cerebrospinal fluid (CSF) in patients who already have a CSF shunt. A CSF shunt is a tube that helps manage conditions like hydrocephalus, which is when there is too much fluid in the brain. The device will be worn by patients to collect important data about how well their shunt is working over a period of 30 days.

To participate in the study, individuals need to be between 5 and 80 years old and have at least one existing CSF shunt, even if it’s not currently functioning. They must also be able to communicate in English about their symptoms and be available for follow-up visits. Participants can expect to wear the device either at home or in a hospital setting, and they will need to provide consent, which can also be given by a parent or guardian for younger participants. This study is important because it aims to improve how doctors monitor shunt function without needing invasive procedures.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. At least one existing ventricular CSF shunt (functional or non-functional, including "virtual off" and ligated, orphaned, abandoned, tied-off, or fractured distal catheters)
  • 2. Region(s) of intact skin overlying at least one unambiguously identifiable chronically indwelling ventricular shunt which crosses the clavicle and is appropriate in size for application of the study device
  • 3. Available for remote and in-person follow-up during the 30-day measurement period (for subjects using the study device at home)
  • 4. Subject is expected to remain in an inpatient setting for sufficient time to complete all required study device measurements (for subjects using the device in an inpatient hospital setting)
  • 5. Signed informed consent by subject or a parent, legal guardian, health care agent, or surrogate decision maker (according to local statutes)
  • 6. Subject or caregiver is able to clearly communicate and document information and shunt symptoms in English
  • 7. Verbal assent by minors 12 years of age and older who are able to understand the study and communicate their decision
  • 8. Patient is at least 5 years old but not more than 80 years old
  • Exclusion Criteria:
  • 1. Presence of an interfering open wound or edema over any portion of the shunt
  • 2. Patient-reported history of adverse skin reactions to adhesives
  • 3. Investigator judges that the subject is likely to be lost to follow-up due to unavailability or clinical outcome being unobtainable
  • 4. Investigator judges that the subject is unlikely to successfully take reliable measurements at home (for subjects using the study device at home)
  • 5. Investigator judges that the subject/subject's caretaker would not be able to successfully place the device without assistance
  • 6. Use of the study device would interfere with standard patient care, or emergency surgery that cannot be delayed, or participation in the study will interfere with, or be detrimental to, administration of optimal healthcare to the subject
  • 7. Participation in any other investigational procedural, pharmaceutical, and/or device study that may influence the collection of valid data under this study

About Rhaeos, Inc.

Rhaeos, Inc. is an innovative biotechnology company dedicated to advancing the field of medical devices through the development of cutting-edge technologies for the management of chronic diseases. Focused on harnessing the power of real-time data and advanced materials, Rhaeos aims to enhance patient outcomes by providing personalized treatment solutions. With a strong commitment to research and development, the company collaborates with leading experts and institutions to drive clinical trials that validate its pioneering products, ultimately transforming the landscape of patient care and improving quality of life for individuals with complex health conditions.

Locations

Chicago, Illinois, United States

Tampa, Florida, United States

Chicago, Illinois, United States

Rolling Meadows, Illinois, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported